Metabotropic glutamate receptors (mGlus), which belong to class C G-protein-coupled receptor (GPCR) family, play key roles in modulating neuronal excitability and synaptic transmission in the central nervous system. The mGlus (mGlu1-8) identified in humans serve as therapeutic targets for a variety of neurological and psychiatric disorders such as Parkinson’s disease, Alzheimer’s disease and schizophrenia, but drugs targeting the mGlus are not currently available.
Click here for original story, Metabotropic glutamate receptor structures reveal potential drug target for neurological diseases
Source: Phys.org